These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy. Spencer K Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639 [TBL] [Abstract][Full Text] [Related]
7. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R; Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982 [TBL] [Abstract][Full Text] [Related]
9. [Prenatal risk assessment of chromosome abnormalities. A combination of ultrasonography and biochemical test--the most effective method]. Conner P; Marsk A; Kublickas M; Almström H; Gustafsson S; Westgren M Lakartidningen; 2006 Nov 8-14; 103(45):3460-3. PubMed ID: 17140176 [No Abstract] [Full Text] [Related]
10. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230 [TBL] [Abstract][Full Text] [Related]
11. [Nuchal translucency and combined test: what are the implications in clinical practice?]. Marchini G; Rosati A; Ribiani E; Romanelli M; Porcaro G; Clerici G Minerva Ginecol; 2010 Jun; 62(3):187-93. PubMed ID: 20595943 [TBL] [Abstract][Full Text] [Related]
12. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
13. Gender impact on first trimester markers in Down syndrome screening. Larsen SO; Wøjdemann KR; Shalmi AC; Sundberg K; Christiansen M; Tabor A Prenat Diagn; 2002 Dec; 22(13):1207-8. PubMed ID: 12478634 [TBL] [Abstract][Full Text] [Related]
14. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation. Herraiz I; López-Jiménez EA; García-Burguillo A; Nieto O; Villar OP; Escribano D; Galindo A Ultrasound Obstet Gynecol; 2009 May; 33(5):518-23. PubMed ID: 19402101 [TBL] [Abstract][Full Text] [Related]
18. Choosing the best prenatal screening protocol. Simpson JL N Engl J Med; 2005 Nov; 353(19):2068-70. PubMed ID: 16282182 [No Abstract] [Full Text] [Related]
19. [Antenatal screening for Down syndrome: a smattering of epidemiology]. Boulvain M; Billieux MH; Irion O Rev Med Suisse; 2008 Oct; 4(176):2276-8, 2280. PubMed ID: 19025178 [TBL] [Abstract][Full Text] [Related]
20. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Spencer K; Nicolaides KH BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]